iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2095

Identifiers

  • Canonical SMILES: 
    CC[C@@H]1NC(=O)[C@H](CCCNC(NC)=NC)NC(=O)[C@@](C)(CCCCNC(=O)[C@H](NC1=O)c1ccccc1)NC(=O)C(C)C
  • IUPAC name: 
    N-[(3R,6S,9S,12R)-9-[3-(N',N''-dimethylcarbamimidamido)propyl]-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-tetraazacyclohexadecan-12-yl]-2-methylpropanamide
  • InChi: 
    InChI=1S/C31H50N8O5/c1-7-22-26(41)38-24(21-14-9-8-10-15-21)28(43)34-18-12-11-17-31(4,39-25(40)20(2)3)29(44)37-23(27(42)36-22)16-13-19-35-30(32-5)33-6/h8-10,14-15,20,22-24H,7,11-13,16-19H2,1-6H3,(H,34,43)(H,36,42)(H,37,44)(H,38,41)(H,39,40)(H2,32,33,35)/t22-,23-,24+,31+/m0/s1
  • InChiKey: 
    DAOYDPRFSPLOQX-UBWFJNMSSA-N

External links


89610269
CHEMBL4116682

External search

Bibliography (1)

Publication Name
Karatas Hacer, Li Yangbing, Liu Liu, Ji Jiao, Lee Shirley, Chen Yong, Yang Jiuling, Huang Liyue, Bernard Denzil, Xu Jing, Townsend Elizabeth C., Cao Fang, Ran Xu, Li Xiaoqin, Wen Bo, Sun Duxin, Stuckey Jeanne A, Lei Ming, Dou Yali, Wang Shaomeng. . Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction Journal of Medicinal Chemistry. 7

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
3 3 0 0

Targets

PPI family Best activity Diseases MMoA
WDR5/MLL 9.00 lymphoid leukemia (disease) Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 614.39 g/mol
HBA 13
HBD 7
HBA + HBD 20
AlogP 0.17
TPSA 183.53
RB 8
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 3 3 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b01796 7 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pKi (inhibition constant, -log10) 9.00
10.1021/acs.jmedchem.6b01796 7 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 8.62
10.1021/acs.jmedchem.6b01796 7 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay AlphaLISA pIC50 (half maximal inhibitory concentration, -log10) 5.90
10.1021/acs.jmedchem.6b01796 7 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition MOLM-13 MOLM-13 pIC50 (half maximal inhibitory concentration, -log10) 4.50
10.1021/acs.jmedchem.6b01796 7 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition MV4-11 MV4-11 pIC50 (half maximal inhibitory concentration, -log10) 4.82
10.1021/acs.jmedchem.6b01796 7 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition HL-60 HL60 pIC50 (half maximal inhibitory concentration, -log10) 4.07
Ta Structure Name Drugbank ID
0.7244 CR665 DB05155
0.6786 D-phenylalanyl-N-benzyl-L-prolinamide DB07143
0.6613 Neocitrullamon DB13396
0.6560 PZ-128 DB11839
0.6555 D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide DB07005
0.6552 D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide DB07133
0.6406 Elamipretide DB11981
0.6400 Antipain DB15251
0.6333 D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide DB07027
0.6283 (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide DB06850
0.6283 N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06858
0.6281 D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide DB06919
0.6281 (R)-Praziquantel DB11749
0.6281 Praziquantel DB01058
0.6250 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06947